Legend Biotech Operating Income 2019-2021 | LEGN

Legend Biotech annual/quarterly operating income history and growth rate from 2019 to 2021. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
  • Legend Biotech operating income for the quarter ending September 30, 2021 was $-0.089B, a 32.52% increase year-over-year.
  • Legend Biotech operating income for the twelve months ending September 30, 2021 was $-0.317B, a 39.57% increase year-over-year.
  • Legend Biotech annual operating income for 2020 was $-0.223B, a 71.67% increase from 2019.
  • Legend Biotech annual operating income for 2019 was $-0.13B, a 8384.16% increase from 2018.
  • Legend Biotech annual operating income for 2018 was $-0.002B, a INF% decline from .
Legend Biotech Annual Operating Income
(Millions of US $)
2020 $-223
2019 $-130
2018 $-2
Legend Biotech Quarterly Operating Income
(Millions of US $)
2021-09-30 $-89
2021-06-30 $-90
2021-03-31 $-81
2020-12-31 $-58
2020-09-30 $-67
2020-06-30 $-55
2020-03-31 $-44
2019-12-31 $-62
2019-09-30 $-28
2019-06-30 $-28
2019-03-31 $-12
2018-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $6.033B $0.076B
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and other indications. The company's lead product consist LCAR-B38M/JNJ-4528, which are in clinical stage. Legend Biotech Corporation is based in Cayman Islands.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.345B 9.06
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.301B 19.14
Biohaven Pharmaceutical Holding (BHVN) United States $7.598B 0.00
Emergent Biosolutions (EBS) United States $2.503B 9.00
Arcus Biosciences (RCUS) United States $2.274B 0.00
Myovant Sciences (MYOV) United Kingdom $1.296B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.081B 0.00
Zymeworks (ZYME) Canada $0.538B 0.00
SQZ Biotechnologies (SQZ) United States $0.203B 0.00
Ambrx Biopharma (AMAM) United States $0.201B 0.00
Enzo Biochem (ENZ) United States $0.155B 20.00